Literature DB >> 16176337

Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments.

Jean-Pierre Boissel1, François Gueyffier, Florent Boutitie, Stuart Pocock, Robert Fagard.   

Abstract

The mechanism of risk reduction obtained by blood pressure-lowering pharmacological treatment remains unclear. We explored the amount of risk reduction attributable to the apparent effect of antihypertensive medicines on blood pressure by using the capture approach. Five randomized, placebo or nil controlled trials with a total of 28,997 subjects and 1,935 cardiovascular fatal or non-fatal events from the INDANA database met the eligibility criteria. Computations were performed on the original individual records using multiple Cox's proportional hazard regression models designed for meeting the assumed treatment mode of action and comparing relevant assumptions. For coronary event, the results are inconclusive essentially because the risk reduction is mild. However, for stroke the risk reduction adjusted for baseline risk factors is 34% (P<0.0001). The part explained by the effect of treatment on systolic blood pressure is 49% of this reduction, with 95% confidence interval not including 100%. This result suggests that the apparent effect on blood pressure is not the only cause of stroke risk reduction in hypertensive subjects submitted to an antihypertensive medicine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16176337     DOI: 10.1111/j.1472-8206.2005.00356.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  7 in total

Review 1.  Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).

Authors:  Marissa N Lassere; Kent R Johnson; Michal Schiff; David Rees
Journal:  BMC Med Res Methodol       Date:  2012-03-12       Impact factor: 4.615

Review 2.  The role of Beta-blockers as first-line therapy in hypertension.

Authors:  Alberto Ranieri De Caterina; Antonio Maria Leone
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

Review 3.  Pharmacotherapy for hypertension in adults aged 18 to 59 years.

Authors:  Vijaya M Musini; Francois Gueyffier; Lorri Puil; Douglas M Salzwedel; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2017-08-16

4.  Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial.

Authors:  F Gueyffier; F Subtil; T Bejan-Angoulvant; Y Zerbib; J P Baguet; J M Boivin; A Mercier; G Leftheriotis; J P Gagnol; J P Fauvel; C Giraud; G Bricca; D Maucort-Boulch; S Erpeldinger
Journal:  J Hum Hypertens       Date:  2014-04-17       Impact factor: 3.012

5.  An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.

Authors:  Anthony Rodgers; Anushka Patel; Otavio Berwanger; Michiel Bots; Richard Grimm; Diederick E Grobbee; Rod Jackson; Bruce Neal; Jim Neaton; Neil Poulter; Natasha Rafter; P Krishnam Raju; Srinath Reddy; Simon Thom; Stephen Vander Hoorn; Ruth Webster
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

6.  Pharmacotherapy for hypertension in adults 60 years or older.

Authors:  Vijaya M Musini; Aaron M Tejani; Ken Bassett; Lorri Puil; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05

Review 7.  First-line drugs for hypertension.

Authors:  James M Wright; Vijaya M Musini; Rupam Gill
Journal:  Cochrane Database Syst Rev       Date:  2018-04-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.